Saturday 17 October 2026
Export CTMX’s income statement to Excel — free account
CytomX Therapeutics, Inc.
CTMX Healthcare Biotechnology
CytomX Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $76.2 million, down 44.8% from fiscal 2024. In the quarter to June 2026, revenue fell 92.4%, EPS fell 7,400.0% and free cash flow fell 14.5%, each against the same quarter a year earlier.
2.27
0.14
−5.81%
Follow CTMX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
8.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.63 | 7.71 | 23.44 | 44.86 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(33.85) | (25.28) | (32.61) | (45.44) | |
P/B ratio |
4.90 | 5.93 | 2.60 | 2.72 | |
Price to Tangible BV |
4.97 | 6.02 | 2.62 | 2.73 | |
EV/Sales |
3.40 | 5.97 | 13.80 | 26.99 | |
EV/EBITDA |
17.38 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.35) | (6.01) | (6.12) | (5.99) | |
EV/FCF |
(5.35) | (6.00) | (6.11) | (5.98) | |
Quick Ratio |
3.54 | 2.98 | 10.21 | 9.25 | |
Current Ratio |
3.64 | 3.09 | 10.38 | 9.36 | |
Net Debt/EBITDA |
8.83 | 4.87 | 17.21 | 13.16 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.76 | 0.56 | 0.16 | 0.07 | |
Operating CF/Net income |
1.09 | 0.79 | 1.40 | 0.87 | |
Capex/Depreciation |
(0.25) | 0.96 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
256.65% | 3,202.71% | 187.54% | 1,241.04% | |
Selling, General and Administrative Expense of Revenue |
107.78% | 1,110.11% | 104.23% | 536.04% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
23.21% | 223.08% | 45.88% | 181.73% | |
Graham Net Nets |
0.19 | 0.16 | 0.38 | 0.36 | |
Graham Number |
2.42 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
12.50% | (0.97%) | (8.75%) | (13.33%) | |
Free Cash Flow Yield |
(13.75%) | (12.90%) | (9.64%) | (10.06%) | |
Revenue per Share |
0.04 | 0.00 | 0.06 | 0.01 | |
Operating CF per Share |
(0.09) | (0.17) | (0.14) | (0.08) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.09) | (0.17) | (0.14) | (0.08) | |
Cash per Share |
0.87 | 0.99 | 1.96 | 1.51 | |
Shareholders Equity per Share |
0.65 | 0.72 | 1.80 | 1.38 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.65 | 0.72 | 1.80 | 1.38 | |
Free Cash Flow |
(15.42) | (23.44) | (25.55) | (18.07) | |
Working Capital |
108.19 | 97.31 | 319.07 | 333.29 | |
Capital Expenditures |
0.13 | (0.20) | — | — | |
Net Current Asset Value |
98.35 | 91.36 | 313.68 | 294.00 | |
EV/EBIT |
16.64 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(0.02) | 0.30 | 0.00 | 0.00 | |
Price to Operating Income |
22.64 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.49 | 2.56 | 1.30 | 19.68 | |
Average Payables |
1.03 | 1.19 | 0.82 | 1.08 | |
Average Assets |
148.62 | 136.05 | 228.93 | 278.14 | |
Average Common Equity |
41.97 | 49.28 | 172.50 | 210.99 |
Columns are period end dates